Clinical biotechnology company Storm Therapeutics has successfully completed a USD $30 million Series B financing round. The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. The financing was co-led by existing investors M Ventures, Pfizer Ventures, Taiho Ventures LLC, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
